Proton vs Photon IMRT Toxicity in Breast Cancer (NCT07537712)
Summary
NIH registered clinical trial NCT07537712, an observational study comparing acute and long-term toxicities between intensity-modulated proton therapy (IMPT) and intensity-modulated photon radiotherapy (IMRT/VMAT) in postoperative breast cancer patients. The study will follow eligible patients for at least one year to assess incidence and severity of toxicities affecting the heart, lungs, skin, esophagus, thyroid, and lymphatic tissues, as well as patient-reported outcomes, cosmetic outcomes, and quality of life. The trial has an estimated completion date of April 17, 2026.
What changed
NIH registered a new observational clinical trial on ClinicalTrials.gov under NCT07537712, titled 'Proton vs Photon IMRT Toxicity in Breast Cancer.' The study is an observational, non-interventional trial comparing intensity-modulated proton therapy (IMPT) against intensity-modulated photon radiotherapy (IMRT/VMAT) in postoperative breast cancer patients, with primary endpoints including acute and late toxicities to critical organs and patient-reported outcomes. Estimated completion date is April 17, 2026.
For healthcare providers, clinical investigators, and medical device manufacturers involved in radiotherapy, this trial registration signals ongoing comparative effectiveness research between proton and photon-based radiation therapies for breast cancer, which may inform future clinical practice patterns and technology adoption decisions. The study's focus on cardiac, pulmonary, and lymphatic toxicities is relevant to radiotherapy safety monitoring and quality assurance programs.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Proton vs Photon IMRT Toxicity in Breast Cancer
Observational NCT07537712 Kind: OBSERVATIONAL Apr 17, 2026
Abstract
This study aims to compare the differences in acute and long-term toxicities between intensity-modulated proton therapy (IMPT) and intensity-modulated photon radiotherapy (IMRT/VMAT) in postoperative breast cancer patients, with a focus on evaluating their impact on critical organs, including the heart, lungs, skin, esophagus, thyroid, and lymphatic tissues. Eligible patients will be followed for at least one year to assess the incidence and severity of both acute and late toxicities, as well as differences in patient-reported outcomes (PROs), cosmetic outcomes following breast-conserving surgery, and overall quality of life.
Conditions: Breast Cancer
Interventions: Intensity-modulated photon radiotherapy (IMRT/VMAT), Intensity-modulated proton therapy (IMPT)
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.